Finnish
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)

Phase I/II Thymus Transplantation With Immunosuppression #950

Vain rekisteröityneet käyttäjät voivat kääntää artikkeleita
Kirjaudu sisään Rekisteröidy
Linkki tallennetaan leikepöydälle
TilaValmistunut
Sponsorit
M. Louise Markert
Yhteistyökumppanit
National Institutes of Health (NIH)
National Institute of Allergy and Infectious Diseases (NIAID)
Enzyvant Therapeutics GmbH
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

Avainsanat

Abstrakti

The study purpose is to determine if cultured thymus tissue implantation (CTTI) (previously described as transplantation) with tailored immunosuppression based on the recipient's pre-implantation T cell population is a safe and effective treatment for complete DiGeorge anomaly. This study will also evaluate whether cultured thymus tissue implantation and parathyroid transplantation with immunosuppression is a safe and effective treatment for complete DiGeorge anomaly and hypoparathyroidism.

Kuvaus

Complete DiGeorge anomaly is a congenital disorder characterized by athymia. Without successful treatment, children remain immunodeficient and usually die by age 2 years. In infants with complete DiGeorge anomaly and no T cells, cultured thymus tissue implantation (CTTI) without immunosuppression resulted in diverse T cell development and good T cell function. Some infants with no thymus have some T cells that presumably developed extrathymically; these T cells can reject a thymus graft.

The purpose of this study is to tailor immunosuppression use for complete DiGeorge anomaly subjects who have some T cells and different T cell function levels. This protocol includes tailored immunosuppression regimens to allow subjects with different T cell function levels to be suppressed adequately.

Patients with complete DiGeorge often have hypoparathyroidism, a life threatening condition. Successful CTTI does not result in improvement of the hypoparathyroidism. The patients must go to the clinic for frequent calcium levels and to the hospital for calcium infusions. These infants are at risk for seizures from low calcium. This study had a parental parathyroid transplant arm for subjects with hypoparathyroidism who require calcium replacement.

Whether or not a subject was enrolled in the parathyroid arm, the immunosuppression regimen the subject received was dependent on the immune findings as stated in the clinical protocol.

Päivämäärät

Viimeksi vahvistettu: 01/31/2020
Ensimmäinen lähetys: 12/19/2007
Arvioitu ilmoittautuminen lähetetty: 12/19/2007
Ensimmäinen lähetetty: 12/23/2007
Viimeisin päivitys lähetetty: 02/20/2020
Viimeisin päivitys lähetetty: 03/08/2020
Ensimmäisten tulosten toimittamispäivä: 12/26/2019
Ensimmäisten QC-tulosten toimittamispäivä: 02/03/2020
Ensimmäisten tulosten päivämäärä: 02/16/2020
: 12/09/2015
: 12/09/2015
: 01/11/2016
Todellinen opintojen alkamispäivä: 12/18/2005
Arvioitu ensisijainen valmistumispäivä: 11/30/2011
Arvioitu tutkimuksen valmistumispäivä: 12/30/2017

Ehto tai tauti

DiGeorge Anomaly
Complete DiGeorge Anomaly
Complete Atypical DiGeorge Anomaly
Complete DiGeorge Syndrome
Complete Atypical DiGeorge Syndrome

Interventio / hoito

Biological: Cultured Thymus Tissue Implantation (CTTI) w/immunosuppression

Other: CTTI with Parathyroid Transplantation w/immunosuppression

Procedure: Blood Draw

Drug: Rabbit anti-thymocyte globulin

Drug: Cyclosporine

Drug: Tacrolimus

Drug: Methylprednisolone or Prednisolone

Drug: Cultured Thymus Tissue Implantation (CTTI) w/immunosuppression

Drug: Cultured Thymus Tissue Implantation (CTTI) w/immunosuppression

Vaihe

Vaihe 1/Vaihe 2

Varren ryhmät

VarsiInterventio / hoito
Experimental: Cultured Thymus Tissue Implantation (CTTI) w/immunosuppression
Patients with complete DiGeorge Anomaly (cDGA) undergo cultured thymus tissue implantation (previously described as transplantation) with tailored immunosuppression based on the subject's pre-implantation T cell numbers and function.
Biological: Cultured Thymus Tissue Implantation (CTTI) w/immunosuppression
Potential thymus recipient subjects are screened for eligibility. Thymus donor (unrelated donor), and thymus donor's birth mother are screened for safety. CTTI is done under general anesthesia in the operating room. Cultured thymus tissue is implanted into the subject's quadriceps. Two to three months post CTTI, if medically stable, the subject undergoes allograft biopsy. At the time of implantation and biopsy, a skin biopsy is done. Immunosuppression is weaned as per protocol.
Experimental: CTTI with Parathyroid Transplantation w/immunosuppression
Patients with complete DiGeorge Anomaly (cDGA) undergoes cultured thymus tissue thymus implantation (previously described as transplantation) with tailored immunosuppression based on the subject's pre-implantation T cell numbers and function. If the patient has hypoparathyroidism, and is eligible, the patient may also receive a parathyroid transplant.
Other: CTTI with Parathyroid Transplantation w/immunosuppression
For subjects w/ hypoparathyroidism, the subject may receive CTTI and parathyroid transplant. For parathyroid transplant, parental parathyroid donors are screened. Parathyroid is harvested from the parent who shares the most Human Leukocyte Antigens (HLA) alleles with the thymus donor. Parathyroid gland is minced and placed in quadriceps muscle; there is no dose. Parathyroid donors are monitored as outpatients until recipients' discharge. Recipients' calcium and PTH levels are monitored indefinitely. Potential thymus recipient subjects are screened for eligibility. Thymus donor (unrelated donor), and thymus donor's birth mother are screened for safety. CTTI is done under general anesthesia in the operating room. Cultured thymus tissue is implanted into the subject's quadriceps. Two to three months post CTTI, if medically stable, the subject undergoes allograft biopsy. At the time of CTTI and biopsy, a skin biopsy is done. Immunosuppression is weaned as per protocol.

Kelpoisuusehdot

Sukupuolet, jotka ovat kelpoisia tutkimukseenAll
Hyväksyy terveelliset vapaaehtoisetJoo
Kriteeri

Thymus Transplantation Inclusion:

- Must have 1 of following: 22q11 or 10p13 hemizygosity; hypocalcemia requiring replacement; congenital heart defect; CHARGE association or CHD7 mutation; or abnormal ears plus mother w/diabetes (type I, type II, gestational).

- <50 CD3+ T cells/cumm or <50 CD3+ T cells/cumm that are CD62L+ CD45RA+ (cluster of differentiation 45RA) (naïve phenotype), or <5% of CD3+ count being CD62L+ CD45RA+

Atypical DiGeorge:

- Must have, or have had, a rash. If rash present, rash biopsy must show T cells in skin. If rash & adenopathy resolved, must have >50/cumm T cells & naive T cell must be <50/cumm or <5% of T cells.

Typical DiGeorge:

- CD3+ CD45RA+ CD62L+ T cells <50/mm3 or <5% of total T cells

Parathyroid Transplantation Additional Inclusion:

- 2 studies in recipient which PTH<5 pg/ml when ionized calcium <1.1 mmol/L. Can be done anytime pre-tx; 1 must be done while at Duke Hospital.

- Parent(s) willing & eligible to be donors

Thymus Transplantation Exclusion:

- Heart surgery <4 wks pre-tx

- Heart surgery anticipated w/in 3 months after proposed tx

- Rejection by surgeon or anesthesiologist as surgical candidate

- Lack of sufficient muscle tissue to accept transplant of 4 grams/m2 BSA

- HIV infection

- Prior attempts at immune reconstitution, such as bone marrow tx or previous thymus tx

- CMV(>500 copies/ml blood by PCR on 2 tests)

- Ventilator dependence

Parathyroid Donor Inclusion:

- >18 years of age

- Serum calcium in normal range

- Normal PTH function

- HLA typing consistent with parentage

- Not on anticoagulation or can come off

- Parent chosen will share HLA-DR allele with thymus donor that was not inherited by the recipient. If no HLA matching at all, then either parent is acceptable if the parent meets other criteria.

Parathyroid Donor Exclusion:

- <18 years old

- Hypoparathyroidism-low PTH in presence of low serum calcium & high serum phosphate

- Hyperparathyroidism(or history)-elevated PTH in presence of high serum calcium and low serum phosphate.

- History of cancer

- Donor only living involved parent/guardian of recipient

- Evidence of HIV-1, HIV-2, HTLV-1, HTLV-2, syphilis, hepatitis B, hepatitis C, West Nile virus, or Chagas disease

- Creutzfeldt Jakob disease (CJD)

- Elevated liver function studies: AST, ALT, alkaline phosphatase >3x upper normal limit

- Receipt of xenograft or risk factors for SARS, CJD and/or smallpox exposure. {If CJD risk factors but not active disease, parent may give permission for parathyroid use.}

- Urine CMV positive

- Positive CMV IgM

- Positive IgM anti-EBV VCA

- On blood thinners and cannot stop for parathyroid donation

- Elevated PT or PTT (>ULN)

- Platelets<100,000

- Positive Toxoplasma IgM

- Donor will receive a history and physical; may be excluded based on PI's medical judgment.

- Hemoglobin <9g/dl

- Infectious head or neck lesion

- Goiter on ultrasound

- Abnormal fiberoptic laryngoscopy of vocal cords

- HLA inconsistent with parentage

- Pregnancy

- Positive HSV IgG isn't exclusion; post-tx prophylaxis needed for recipient if donor is HSV IgG+.

- Positive VZV IgG isn't exclusion; post-tx prophylaxis needed if donor is VZV IgG+.

- Medical concern of independent otolaryngologist.

- Concern by medical psychologist/social worker that potential donor isn't competent or does not understand risks.

- Questionnaire responses can lead to exclusion.

Mother of DiGeorge Inclusion:

• Provides consent to use blood/buccal sample. No exclusions except unwillingness to consent; or, provide blood/buccal sample.

Tulokset

Ensisijaiset tulosmittaukset

1. Survival at 1 Year Post-CTTI [1 year post-CTTI]

Survival at 1 year post cultured thymus tissue implantation was assessed using the Kaplan Meier Estimated Survival. This mathematical function estimates the survival for a certain length of time.

Toissijaiset tulosmittaukset

1. Survival at 2 Years Post-CTTI [2 years post-CTTI]

Survival at 2 years post cultured thymus tissue implantation was assessed using the Kaplan Meier Estimated Survival. This mathematical function estimates the survival for a certain length of time.

2. Immune Reconstitution Efficacy - Total CD3 T Cells [1 year post-CTTI]

The development of total CD3 T cells at one year as measured using flow cytometry

3. Immune Reconstitution Efficacy - Total CD4 T Cells [1 year post-CTTI]

The development of total CD4 T cells at one year as measured using flow cytometry

4. Immune Reconstitution Efficacy - Total CD8 T Cells [1 year post-CTTI]

The development of total CD8 T cells at one year as measured using flow cytometry

5. Immune Reconstitution Efficacy - Naive CD4 T Cells [1 year post-CTTI]

The development of total naive CD4 T cells at one year as measured using flow cytometry

6. Immune Reconstitution Efficacy - Naive CD8 T Cells [1 year post-CTTI]

The development of total naive CD8 T cells at one year as measured using flow cytometry

7. Immune Reconstitution Efficacy - Response to Mitogens [1 year post-CTTI]

Measurement of the T cell proliferative response to the mitogen phytohemagglutin (PHA).

8. Thymus Allograft Biopsy [2 to 3 months post-CTTI]

Evidence, on biopsy of the thymus tissue implanted in muscle, that shows the development of new T cells.

Liity facebook-sivullemme

Täydellisin lääketieteellinen tietokanta tieteen tukemana

  • Toimii 55 kielellä
  • Yrttilääkkeet tieteen tukemana
  • Yrttien tunnistaminen kuvan perusteella
  • Interaktiivinen GPS-kartta - merkitse yrtit sijaintiin (tulossa pian)
  • Lue hakuusi liittyviä tieteellisiä julkaisuja
  • Hae lääkekasveja niiden vaikutusten perusteella
  • Järjestä kiinnostuksesi ja pysy ajan tasalla uutisista, kliinisistä tutkimuksista ja patenteista

Kirjoita oire tai sairaus ja lue yrtteistä, jotka saattavat auttaa, kirjoita yrtti ja näe taudit ja oireet, joita vastaan sitä käytetään.
* Kaikki tiedot perustuvat julkaistuun tieteelliseen tutkimukseen

Google Play badgeApp Store badge